Top of this page
Skip navigation, go straight to the content

Research & development

Research & Development

UCB’s goal is to command a leading position in discovering and developing new therapies to treat patients suffering from severe diseases. With one of the strongest pipelines in the sector, our focus is on neurological disorders, inflammatory diseases and cancer to provide new treatments for specialists and their patients

Research & Development
 

Our key features

  • Patients are at the heart of all we do, driving our commitment to the treatment of severe diseases
  • A focus on three key therapeutic areas: CNS, inflammation and oncology
  • A development pipeline of twelve new compounds - NCEs and NBEs - targeting sixteen separate indications
  • An international R&D organisation with over 2,000 staff
  • A track record of successful partnerships with both academia and leading drug discovery organisations.  Partnership is part of our philosophy

One team approach

Our philosophy is to have a 'one team' approach to drug discovery and development with seamless integration of research, development and commercial colleagues, in a process of continual learning and confirming as we examine our data and capitalise on our knowledge. Our people